"It's not very often that a new therapy comes along that has as much potential as this new, leadless pacemaker does," said Vance Plumb, M.D., professor of medicine in the Division of Cardiovascular Disease in the School of Medicine. "Historically, the weak link causing failure of pacing has been the leads, which this device eliminates. It's a big step forward in patient treatment and a milestone for cardiac rhythm treatment in Alabama."
Louis Brunsting, M.D, associate professor of surgery and chief of the Section of Minimally Invasive Cardiac Surgery at the University of Alabama at Birmingham and Massoud Leesar, M.D., professor of medicine and chief of the Section of Interventional Cardiology, modified the procedure to take place over three days instead of all at one time to decrease the risk of bleeding a patient could endure due to blood-thinning medication taken prior to the stenting procedure.
Methotrexate -- the inexpensive anchor drug for the treatment of rheumatoid arthritis -- isn't being used optimally today, with few patients switching from the oral to the subcutaneous formulation or adding a second conventional disease-modifying anti-rheumatic drug (DMARD) before turning to a biologic, researchers found.
Researchers at the University of Alabama at Birmingham have shed new light on how cells called gliomas migrate in the brain and cause devastating tumors. The findings, published June 19, 2014 in Nature Communications, show that gliomas — malignant glial cells — disrupt normal neural connections and hijack control of blood vessels.